Systemic Therapy in Soft Tissue Sarcomas: Past, Present and Future

Purohit, Samit; Bhise, Rohan; Appachu, Sandhya; Lakshmaiah, K C; Govindbabu, K.

doi:10.1007/s13193-012-0140-8

Cited by 9 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To solve the problem that few options exist for the treatment of advanced sarcomas, researchers are doing intensive work in this field. Because of the hypersensitivity of STS, targeted therapies with better tolerance and less side effects are quite promising (Shukla et al, 2011;Purohit et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Endostar^®Combined with Chemotherapy in Patients with Advanced Soft Tissue Sarcomas

Zhang

Liao²,

Xu³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Soft tissue sarcomas (STS) are a heterogeneous group of tumors, and approximately 40-50% of patients with STS develop metastatic disease. The median overall survival of those patients was 12 months and their 5-year survival rate was 8%. Therefore, study on more effective treatment, especially the targeting therapies, is urgently needed. Objective: To evaluate the efficacy and safety of Endostar® combined with chemotherapy in patients with advanced STS. Methods: A retrospective case-series study was conducted in Cancer Institute of PLA, Xinqiao Hospital. A total of 71 patients suffering from advanced STS (IIB -IV) were included, of whom 49 cases treated with chemotherapy alone were defined as the control group and the rest 22 cases treated with the traditional chemotherapy combined with Endostar® were defined as the test group. The short-term therapeutic effects including objective response rate (ORR), disease control rate (DCR) and safety were evaluated in the two groups. In the follow-up, progression-free survival (PFS) and overall survival (OS) were also observed. Results: In the test and control groups, the ORR was 18.2% and 12.2%, respectively (P = 0.767), and the DCR was 86.4% and 61.2%, respectively (P=0.034). The median time to progression in the test and control groups was 120 days and 70 days with significant difference (P = 0.017), while the median overall survival was 452 days and 286 days without significant difference (P = 0.503). The one-year survival rate in the test group and control group was 56.2% and 35.4%, respectively, while the two-year survival rate was 30.2% and 26.5%, respectively. No significant difference in the side effects was found between the two groups. Conclusions: Endostar® combined with chemotherapy resulted in a higher DCR and longer PFS in the patients with advanced STS, and the toxicity was tolerable.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Endostar^®Combined with Chemotherapy in Patients with Advanced Soft Tissue Sarcomas

Zhang

Liao²,

Xu³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…However, they are commonly seen in extremities, trunk and pelvis and the head and neck (1). They are usually treated with surgery, chemotherapy (particularly for Ewing's and rhabdomyosarcoma (2)) and biological therapies aimed at mutated tumourspecific oncogenes (3). Unfortunately, these therapeutic modalities produce cure rates of at the most 30% (4), principally because sarcomas are commonly diagnosed at an advanced stage (1,4).…”

Section: Introductionmentioning

confidence: 99%

“…

Objective:We report on the incidence and the gender, age and ethnic distribution of sarcomas diagnosed between 1980 and 2008 in the multi-ethnic Republic of Suriname. Methods: Total and average yearly number of cases, crude rates, as well as relevant population data were derived from the records of the Pathologic Anatomy Laboratory and the General Bureau of Statistics, respectively, and stratified according to gender, age groups [0][1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] and the largest ethnic groups (Hindustani, Creole, Javanese and Maroons). Results: Between 1980 and 2008, 258 sarcomas were diagnosed in Suriname, ie at a frequency of nine per year and an annual rate of two per 100 000.

…”

mentioning

confidence: 99%

Incidence, as Well as Gender, Age and Ethnic Distribution of Sarcomas in the Republic of Suriname from 1980 to 2008

et al. 2014

View full text Add to dashboard Cite

show abstract

“…This is in stark contrast to the management of STS where RT has been shown to have a clear benefit in conjunction with surgical management [32–35]. One possible explanation is that Ewing sarcoma is a highly chemosensitive disease in contrast to other STSs [36]. Considering this and our findings, we suspect that the inherent chemosensitivity of EES coupled with improved systemic regimens may have been able to adequately control residual microscopic disease in the absence of adjuvant RT.…”

Section: Discussionmentioning

confidence: 61%

Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskeletal Ewing Sarcoma

et al. 2020

View full text Add to dashboard Cite

Objectives We reviewed our experience treating patients with localized extraskeletal Ewing sarcoma (EES) to determine optimal local management strategies for this rare disease. Methods Sixty patients with localized EES treated at our institution between 1994 and 2018 were reviewed. The Kaplan‐Meier method was used to estimates disease outcomes. Results The median follow‐up time was 74 months (interquartile range [IQR], 17–121). Half the patients (n = 30) received combined‐modality local therapy (CMT) with both surgery and radiation therapy (RT), whereas the other half received single‐modality local therapy (SMT) with either surgery or RT. All patients received chemotherapy. The 5‐year overall survival was 76%. Twenty‐two patients (37%) developed recurrence at a median time of 15 months (IQR, 5–56 months) resulting in 3‐year progression‐free survival (PFS) of 65%. On univariate analysis, the use of both neoadjuvant and adjuvant chemotherapy was associated with improved 5‐year PFS (71% vs. 50%, p = .04) compared with those who received one or the other. Furthermore, 11 patients (18%) developed local recurrences at a median time of 14 months (IQR, 2–19 months), resulting in a 5‐year local control (LC) rate of 77%. Use of CMT was not associated with improved LC (83% vs. 72% SMT, p = .41). Also, use of CMT was the only factor associated with poorer disease‐specific survival (vs. SMT; hazard ratio, 3.4; p = .047; 95% confidence interval, 1.01–11.4). Conclusion For patients with EES, CMT was not associated with a decreased rate of local relapse. These data suggest that SMT alone may be sufficient for LC in select patients. A multi‐institutional collaborative effort should be considered to validate these findings. Implications for Practice Extraskeletal Ewing sarcoma is a rare chemosensitive sarcoma whose clinical course more closely follows Ewing sarcoma of bone rather than that of other soft tissue sarcomas. Based on this study, combined‐modality local therapy did not confer a local control advantage compared with single‐modality local therapy. Therefore, single‐modality local therapy is likely adequate in select patients with favorable disease features, which has the advantage of ensuring prompt administration of systemic therapy. A multi‐institutional collaborative effort is warranted to determine which patients may benefit from de‐escalated local therapy.

show abstract

Systemic Therapy in Soft Tissue Sarcomas: Past, Present and Future

Cited by 9 publications

References 20 publications

Efficacy and Safety of Endostar^®Combined with Chemotherapy in Patients with Advanced Soft Tissue Sarcomas

Efficacy and Safety of Endostar^®Combined with Chemotherapy in Patients with Advanced Soft Tissue Sarcomas

Incidence, as Well as Gender, Age and Ethnic Distribution of Sarcomas in the Republic of Suriname from 1980 to 2008

Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskeletal Ewing Sarcoma

Contact Info

Product

Resources

About

Systemic Therapy in Soft Tissue Sarcomas: Past, Present and Future

Cited by 9 publications

References 20 publications

Efficacy and Safety of Endostar®Combined with Chemotherapy in Patients with Advanced Soft Tissue Sarcomas

Efficacy and Safety of Endostar®Combined with Chemotherapy in Patients with Advanced Soft Tissue Sarcomas

Incidence, as Well as Gender, Age and Ethnic Distribution of Sarcomas in the Republic of Suriname from 1980 to 2008

Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskeletal Ewing Sarcoma

Contact Info

Product

Resources

About

Efficacy and Safety of Endostar^®Combined with Chemotherapy in Patients with Advanced Soft Tissue Sarcomas

Efficacy and Safety of Endostar^®Combined with Chemotherapy in Patients with Advanced Soft Tissue Sarcomas